

ENGOT ov 29




Sponsor: **ARCAGY-GINECO**

Principal Investigator: **J.E. KURTZ**


Status: **RECRUITING**

ATEzolizumab and Avastin in LAte recurrent disease

ATALANTE DESIGN



145 patients in 37 active sites in France



▪ Safety

Following the 3 IDMC, the recommendation of the experts is to pursue the protocol but management of hematological toxicity and bevacizumab toxicities of interest must be closely followed.

• International

Participating Groups: AGO, AGO-A, BGOG, CEEGOG, GEICO, ISGO

Submission to competent authorities: Thank to AGO Austria and GEICO!

We are waiting for the other groups to submit in November.

=> The First international patient is expected in December/January!